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Introduction
This article discusses the epidemiology and evidence of known or proposed mechanisms of 
environmental, chemical, infectious, and perinatal exposures as they pertain to the 
development of pediatric allergy and asthma. This article will conclude by reviewing novel 
diagnostic techniques and therapeutic interventions to help clinicians mitigate asthma 
morbidity.
The prevalence of asthma is rising, affecting approximately 26 million people in the United 
States and nearly 9.6% of children in the United States.1 The annual direct cost of asthma in 
the United States is $50 billion, with the cost of an emergency department visit nearly 5 
times the cost of an office visit.2 Asthma does not affect all pediatric populations equally, 
with disproportionate burdens on children from minority and impoverished backgrounds.3
Risk Factors
Perinatal Influences
The German Perinatal Asthma and Environment Long-Term Allergy Study consisted of a 
comprehensive assessment of pregnancy-related and early life factors and asthma outcomes 
from birth through 5 years of age.4 Repeated common colds during pregnancy were 
associated with an increased risk of wheezing outcomes, independent of medication intake 
or concomitant fever.4 A review analysis by Ciaccio and Girdhar5 highlighted 2 studies that 
showed compelling protective evidence of maternal ω-3 fatty acid supplementation and 
infant allergy. The data suggested that offspring of women who took long-chain ω-3 
polyunsaturated fatty acids during pregnancy and while breastfeeding had significantly 
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lower odds of developing eczema. The investigators postulated potential protective 
mechanisms, such as through an “anti-inflammatory intestinal microbiome,” contributing to 
sensitization development.5 This article contributes to the conflicting literature of the role of 
fatty acids and pediatric allergy.
Chemical and Environmental Exposures
New evidence explores the effects of high- and low-molecular-weight phthalates, pesticides 
such as dichlorophenols, and broad-spectrum antimicrobials such as triclosan exposure and 
their impact on the microbiome and asthma development and morbidity. In addition to 
immunomodulatory effects, dichlorophenols are airway irritants. Using the US National 
Health and Nutritional Examination Survey, urinary dichlorophenol levels in the upper 
tertile were associated with atopic wheezing, physician-diagnosed asthma, worse asthma 
morbidity, and elevated IgE levels.6 A study with similar methodology, which used 
cumulative National Health and Nutritional Examination Survey data to assess the impact of 
triclosan on asthma prevalence and control, found an approximately 70% increased risk of 
reporting an asthma exacerbation in the last year in those with higher urinary triclosan 
metabolites. 7 Multiple studies have suggested that urinary biomarkers of phthalates, 
specifically higher-molecular-weight phthalates, which are used in plastics, are associated 
with allergies and asthma.8 A review article by North et al8 highlighted that oxidative stress 
markers and phthalate metabolites in urine have recently been linked to decrements in 
pulmonary function, with effect modifications by polymorphisms in oxidative stress-related 
genes. This review stressed that oxidative stress-mediated lung dysfunction might be an 
important mechanism of phthalate toxicity related to asthma.8 Those with an allergic disease 
and/or asthma could have higher levels of dichlorophenols, triclosan, and phthalates because 
of increased medication or personal care product use. As a scientific community, we are 
unable to assume causation versus reverse causation without further longitudinal and 
immunologic studies.
Infectious Agents
Several prior epidemiologic studies and experimental models have suggested infection with 
Toxocara canis—roundworms of dogs—contributes to the development of allergic 
diseases.9 A pivotal meta-analysis conducted by Li et al,9 including 10 studies with more 
than 1,500 participants, suggested that a positive relation exists between T canis infection 
and asthma.
Illi et al4 demonstrated a consistent inverse association between wheezing and atopic 
outcomes and endotoxin levels in a child’s mattress. The effects of the endotoxin from a 
child’s bed might be due to reverse causation, and thus endotoxin might not be protective 
against the development of atopic outcomes; rather, children with atopy might have lower 
levels of endotoxin released from the gut or skin compared with children without atopy.
Comorbid Conditions
A Perspective piece by Permaul et al10 highlighted the proposed pathogenesis that links 
obesity and asthma and suggested a discrete clinical asthma phenotype in obese children that 
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differentiates them from the larger pediatric asthmatic population. Previous literature has 
demonstrated an association between obesity and the incidence, prevalence, and morbidity 
of asthma. A well-known cohort, the International Study of Asthma and Allergies in 
Childhood phase II in Germany, has provided conflicting evidence to this concept. This 
study showed that increases in body mass index from childhood to adolescence were linked 
to increased incidence and persistence of rhinitis but were not associated with increases in 
atopic or respiratory diseases universally.11 Previous literature has demonstrated an 
association between obesity and prevalence and morbidity of asthma. Potentially, there 
might be a threshold for obesity to have a causative effect in triggering atopic disease, such 
as the extreme spectrum of obesity. A morbidly obese subset was not examined in this 
cohort.11
Novel Diagnostic Techniques
Several articles in the Annals during 2014 focused on the evolving role of fraction of 
exhaled nitric oxide (FeNO) and asthma diagnostics, guiding medication treatment decisions 
in asthma care.12–16 FeNO monitors eosinophilic-mediated small airway inflammation and 
has been proposed as a potential biomarker for monitoring the progression of asthma.17 A 
review study published by Ritz and Trueba12 found substantial evidence that anxiety, 
negative affect, and acute stress have a positive association with FeNO in asthma, whereas 
chronic stress and depression are more conflicting and were found to have an inverse 
association with FeNO. Proposed pathophysiologic mechanisms have suggested that these 
conflicting associations are mediated through other pathways such as increased oxidative 
stress or arginase resulting in decreased measurable FeNO.12
Articles published in the Annals have helped contribute to the ongoing discourse on the 
utility of FeNO measurements in routine asthma care. A study conducted by Chipps et al16 
looked at a subset of the population with FeNO greater than 100 ppb, and a study by 
LaForce et al14 examined the impact of FeNO on clinical decision making. Most 
importantly, these small observational studies highlighted the need for randomized 
controlled longitudinal studies to further understand the role of FeNO in the pediatric and 
adult populations. If studied further, FeNO has the potential to guide treatment decisions to 
result in decreased asthma morbidity and health care usage.14–16 Three articles focused on 
the utility of the noninvasive Asthma Predictive Index, the role of methacholine challenge 
tests, and thresholds of provocative concentrations, respectively, and the ability of each to 
diagnose and guide treatment decisions in patients with mild asthma.18–20
Therapeutic Interventions
The role of omalizumab, anti-IgE therapy in severe refractory asthma and respiratory 
diseases in general, was highlighted in the 2014 issues of Annals. A review study by Bonini 
et al21 focused on the evidence behind omalizumab in the treatment of respiratory diseases. 
This review referenced a 28-week randomized double-blinded, placebo-controlled trial in 
patients with moderate to severe asthma, which demonstrated a significant decrease in 
asthma exacerbations and improvements in asthma and rhinitis symptom scores.21 Although 
a US Food and Drug Administration safety subcommittee and the United Kingdom National 
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Institute for Health and Clinical Excellence voted in favor of recommending omalizumab in 
children 6 to 11 years of age, this therapy is still awaiting formal approval in this age 
group.22
Several studies also focused on the potential benefit of heliox-driven nebulized β2-agonists 
and early administration of intravenous β-agonists, such as terbutaline, on asthma 
outcomes.23–25 A pivotal promising review and meta-analysis conducted by Rodrigo and 
Castro-Rodriguez25 indicated that among the 3 pediatric studies, β2-agonist heliox-driven 
nebulization significantly decreased the severity of exacerbations in children as measured by 
asthma or pulmonary severity composite scores. Pooled analysis of 7 trials, which included 
children, showed significantly lower rates of hospital admissions. This meta-analysis 
concluded that treatment of 9 patients with this heliox delivery method prevented 1 patient 
from undergoing hospitalization compared with standard oxygen-driven nebulization.25 A 
retrospective study conducted by Doymaz et al24 suggested that early administration of 
intravenous terbutaline in pediatric asthma significantly decreased respiratory failure and 
need for mechanical ventilation in the largest cohort to date of pediatric patients with severe 
asthma.23,24 One limitation of this study is that, in addition to early administration of 
intravenous terbutaline, the treatment vs control groups initiated their medical care at 
different medical facilities. However, this study corroborated previous work that suggests 
the response to inhaled bronchodilators varies with severity of airway obstruction and 
highlighted the need for larger prospective trials of intravenous β-agonists in the emergency 
management of severe pediatric asthma exacerbations.24
Conclusion
This year in review highlights a portion of the articles related to pediatric allergy and asthma 
in the Annals in 2014. The next year has the promise of answering several pivotal questions 
related to exposure, at-risk populations, and the evolving diagnostic and therapeutic areas of 
asthma care.
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